Michael Kohrman

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

David Neal Franz, Steven Sparagana, E. Martina Bebin et al. · The Lancet · 2012 · 771 citations

Tuberous Sclerosis Complex, Neuro-oncology, Placebo-controlled Phase 3 +7

ECoG gamma activity during a language task: differentiating expressive and receptive speech areas

Vernon L. Towle, Hyunah Yoon, Melanie Castelle et al. · Brain · 2008 · 237 citations · Full text

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

David Neal Franz, Steven Sparagana, E. Martina Bebin et al. · PLoS ONE · 2016 · 203 citations · Full text

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

David Neal Franz, Steven Sparagana, E. Martina Bebin et al. · The Lancet Oncology · 2014 · 176 citations

Tuberous Sclerosis Complex, Neuro-oncology, Glioma +9

Oral Nonprescription Treatment for Insomnia: An Evaluation of Products With Limited Evidence

Amy Meoli, Carol L. Rosen, David A. Kristo et al. · Journal of Clinical Sleep Medicine · 2005 · 154 citations · Full text